Future Projections: Calcitonin Gene-Related Peptide Receptor Antagonist Market to Reach $3.48 Billion by 2029 at 11% CAGR
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Latest Market Insights for the Calcitonin Gene-Related Peptide Receptor Antagonist Industry?
The market size for calcitonin gene-related peptide receptor antagonists has experienced a rapid expansion in recent years. The market value is projected to increase from $2.06 billion in 2024 to $2.30 billion in 2025, marking a compound annual growth rate (CAGR) of 11.2%. Factors that contributed to growth in the past include expanded clinical trials proving effectiveness, a rise in global healthcare spending, an uptick in the detection rates of migraine disorders, increased usage of preventive migraine treatments, and a robust pipeline of CGRP antagonist molecules.
The market size of the calcitonin gene-related peptide receptor antagonist is projected to see swift expansion in the coming years, ballooning to $3.48 billion in 2029 with a compound annual growth rate (CAGR) of 11.0%. The anticipated growth in this forecasted period is due to factors such as positive regulatory authorizations, burgeoning research funds, growing use of innovative migraine preventative treatments, along with an increasing elderly population. Key trends projected for this forecasted period involve the development of oral small molecules, wearable devices for triggered dosing, enduring injectable formulas, nanoparticle drug transports, and investigative gene therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25715&type=smp
What Forces Are Driving The Growth Of The Calcitonin Gene-Related Peptide Receptor Antagonist Industry?
The growing occurrence of migraines is anticipated to drive the expansion of the calcitonin gene-related peptide receptor antagonist market. A migraine is characterized by severe throbbing pain usually on one side of the head. The rise in migraines can be attributed to increased stress levels due to hectic urban lifestyles, disrupted sleeping patterns, and higher exposure to noise, pollution, and bright lights as urbanization progresses. This antagonist works to combat migraines by inhibiting CGRP, a protein that amplifies blood vessels and conveys pain signals during a migraine episode, thus diminishing the headache pain and other associated symptoms. For instance, a report released in April 2024 by the National Library of Medicine, a US-based national library, reveals that approximately 61,204 individuals in the US received a migraine diagnosis from a medical professional in 2022, an upsurge of 5.5% compared to 2021. Hence, the escalating incidence of migraines is spearheading the growth of the calcitonin gene-related peptide receptor antagonist market.
What Is The Overview Of Market Segmentation In The Calcitonin Gene-Related Peptide Receptor Antagonist Industry?
The calcitonin gene-related peptide receptor antagonist market covered in this report is segmented –
1) By Type: Small Molecule Antagonists, Monoclonal Antibodies, Peptide-Based Antagonists
2) By Drug Type: Zavegepant, Ubrogepant, Olcegepant, Telcegepant, Rimegepant, Other Drug Types
3) By Application: Migraine Treatment, Pain Management, Cardiovascular Conditions, Bone Disorders
4) By End-Users: Hospitals, Clinics, Homecare Settings, Pharmaceutical Companies
Subsegments:
1) By Small Molecule Antagonists: Oral Small Molecule Antagonists, Intranasal Small Molecule Antagonists, Injectable Small Molecule Antagonists
2) By Monoclonal Antibodies: Erenumab, Fremanezumab, Galcanezumab, Eptinezumab
3) By Peptide-Based Antagonists: CGRP Fragment-Based Antagonists, Peptidomimetic CGRP Antagonists
What Future Market Trends Are Projected For The Calcitonin Gene-Related Peptide Receptor Antagonist Industry?
Leading companies in the calcitonin gene-related peptide receptor antagonist market are concentrating on gaining approvals for innovative products such as oral CGRP receptor antagonists to increase the effectiveness of migraine treatments, broaden therapeutic indications, and provide more user-friendly administration routes. Oral CGRP receptor antagonists are noted as small-molecule medications that obstruct CGRP, a protein associated with migraine onset, aiding in the prevention of migraines. For example, in April 2023, AbbVie Inc., a biotech corporation based in the U.S., obtained permission from the U.S. Food and Drug Administration (FDA) to deploy QULIPTA (atogepant), intended for adult chronic migraine treatment. QULIPTA (atogepant) is a daily oral calcitonin gene-related peptide (CGRP) receptor antagonist, developed for the prevention of adult migraines and now authorized for both episodic and chronic migraine in the U.S. Its mode of operation involves the suppression of CGRP activity—a protein that heightens during migraines and contributes to pain signaling and brain inflammation. QULIPTA is available in 10 mg, 30 mg, and 60 mg tablet dosages, with the 60 mg dose specifically assessed for chronic migraine prevention.
Who Are The Primary Players Operating Across The Global Calcitonin Gene-Related Peptide Receptor Antagonist Market?
Major companies operating in the calcitonin gene-related peptide receptor antagonist market are Pfizer Inc., Merck & Co. Inc. , AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Sosei Group Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A., Alder BioPharmaceuticals, Inc. , H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd., Biosynth Carbosynth , Seurat Therapeutics Inc., Satsuma Pharmaceuticals Inc., Allergan plc , Brise Pharmaceutical (Shanghai) Co Ltd., Nuvie Biopharma Inc.
Get The Full Report Here:
Which Region Offers The Most Growth Potential For The Calcitonin Gene-Related Peptide Receptor Antagonist Market Through 2029?
North America was the largest region in the calcitonin gene-related peptide receptor antagonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide receptor antagonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=25715&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
